An overview of cholera vaccines and their public health implications

Current Opinion in Pediatrics

Volumn 24, Issue 1, 2012, Pages 85-91

  Desai, Sachin N ^a   Clemens, John D ^a  

^a International Vaccine Institute   (South Korea)

Author keywords

cholera; oral cholera vaccine; Vibrio cholerae

Indexed keywords

CHOLERA VACCINE; MORCVAX; MUTACHOL; SHANCHOL; UNCLASSIFIED DRUG;

AWARENESS; CHOLERA; CLIMATE CHANGE; DRUG EFFICACY; ENDEMIC DISEASE; EPIDEMIC; HUMAN; PANDEMIC; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REVIEW; SANITATION; VACCINATION; VIBRIO CHOLERAE; VIRUS PATHOGENESIS; WATER SUPPLY; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; CHILD; CHILD, PRESCHOOL; CHOLERA; CHOLERA VACCINES; DEVELOPING COUNTRIES; DISEASE OUTBREAKS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PUBLIC HEALTH; VACCINATION; VIBRIO CHOLERAE; WATER SUPPLY;

EID: 84856121384     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32834eb625     Document Type: Review

References (43)

1. Siddique AK, Nair GB, Alam M, et al. El Tor cholera with severe disease: a new threat to Asia and beyond. Epidemiol Infect 2010; 138:347-352. Description of new variant V. cholerae 01 El Tor strain that produces a classical cholera toxin, which has been noted to cause more clinically severe disease.
2. Ryan ET. The cholera pandemic, still with us after half a century: time to rethink. PLoS Negl Trop Dis 2011; 5:e1003.
3. Faruque ASG, Alam K, Malek MA, et al. Emergence of multidrug-resistant strain of Vibrio cholerae O1 in Bangladesh and reversal of their susceptibility to tetracycline after two years. J Health Popul Nutr 2007; 25:241-243. (Pubitemid 47604202)
4. Health Cluster Bulletin #28, Pan American Health Organization (2011). http://new.paho.org/hai/index.php?lang=en. [Accessed 14 October 2011]
5. World Health Organization. Cholera, 2009. Weekly Epidemiological Record 2010; 85:293-307.
6. Zuckerman JN, Rombo L, Fisch A. The true burden and risk of cholera: implications for prevention and control. Lancet Infect Dis 2007; 7:521-530. (Pubitemid 47079151)
7. Deen JL, von Seidlein L, Sur D, et al. The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Negl Trop Dis 2008; 2:e173.
8. Huq A, Sack RB, Nizam A, et al. Critical factors influencing the occurrence of Vibrio cholerae in the environment of Bangladesh. Appl Environ Microbiol 2005; 71:4645-4654. (Pubitemid 41129521)
9. Sanchez J, Holmgren J. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr Opin Immunol 2005; 17:388-398. (Pubitemid 40848541)
10. Cash RA, Music SI, Libonati JP, et al. Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J Infect Dis 1974; 130:325-333.
11. Albert MJ, Alam K, Rahman AS, et al. Lack of cross-protection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with V. cholerae O139 Bengal. J Infect Dis 1994; 169:709-710. (Pubitemid 24063035)
12. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nature Med 2005; 11 (4 Suppl):S45-S53. (Pubitemid 40562303)
13. Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol 2010; 8:129. Outlines advantages and measures that may enhance effectiveness of oral immunization in developing countries.
14. Shin S, Desai SN, Sah BK, Clemens JD. Oral vaccines against cholera. Clin Infect Dis 2011; 52:1343-1349. Recent review outlining licensed and new generation oral cholera vaccines.
15. Background Paper on the integration of Oral Cholera Vaccines into Global Cholera Programmes. World Health Organization Strategic Advisory Group of Experts (SAGE) on Immunization. 2009; 1-74.
16. Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990; 335:270-273. (Pubitemid 20047723)
17. Frew S, Liu V, Singer P. A business plan to help the 'global South' in its fight against neglected diseases. Health Affairs 2009; 28:1760-1773.
18. Richie EE, Punjabi NH, Sidharta YY, et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000; 18:2399-2410. (Pubitemid 30156811)
19. Sur D, Kanungo S, Sah BK, et al. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis 2011; 5:e1289. Ongoing phase 3 randomized placebo-controlled trial in over 67 000 adults and children demonstrating 66% efficacy of an affordable modified killed whole cell oral cholera vaccine.
20. Lucas MES, Deen JL, von Seidlein L, et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 2005; 352:757-767. (Pubitemid 40271170)
21. Clemens JD, Sack DA, Harris JR, et al. Cross-protection by B subunitwhole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 1988; 158:372-377.
22. Peltola H, Siitonen A, Kyronseppa H, et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991; 338:1285-1289.
23. Anh DD, Canh DG, Lopez AL, et al. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 2007; 25:1149-1155. (Pubitemid 44963512)
24. Mahalanabis D, Lopez AL, Sur D, et al. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS ONE [Electronic Resource] 2008; 3:e2323.
25. Kanungo S, Paisley A, Lopez A, et al. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine 2009; 27:6887-6893.
26. Tacket CO, Losonsky G, Nataro JP, et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis 1992; 166:837-841.
27. Calain P, Chaine J-P, Johnson E, et al. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine 2004; 22:2444-2451. (Pubitemid 38757343)
28. Ryan E, Calderwood S, Qadri F. Live attenuated oral cholera vaccines. Exp Rev Vaccines 2006; 5:483-494. (Pubitemid 44627880)
29. Chowdhury M, Sheikh A, Qadri F. Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009. Exp Rev Vaccines 2009; 8:1643-1652.
30. Garcia L, Jidy MD, Garcia H, et al. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun 2005; 73:3018-3024. (Pubitemid 40570371)
31. Mahalanabis D, Ramamurthy T, Nair GB, et al. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response. Vaccine 2009; 27:4850-4856.
32. Liang W, Wang S, Yu F, et al. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108. Infect Immun 2003; 71:5498-5504. (Pubitemid 37205600)
33. Ali M, Emch M, von Seidlein L, et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 2005; 366:44-49. (Pubitemid 40956529)
34. Jeuland M, Cook J, Poulos C, et al., Group DCES. Cost-effectiveness of newgeneration oral cholera vaccines: a multisite analysis. Value Health 2009; 12:899-908.
35. World Health Organization. Cholera vaccines: WHO position paper. Weekly Epidemiological Record 2010; 85:117-128. Recent WHO position paper backing the use of oral cholera vaccines in endemic situations and consideration for outbreak settings.
36. Waldor MK, Hotez PJ, Clemens JD. A national cholera vaccine stockpile: a new humanitarian and diplomatic resource. N Engl J Med 2010; 363:2279-2282.
37. Chaignat C-L, Monti V, Soepardi J, et al. Cholera in disasters: do vaccines prompt new hopes? Exp Rev Vaccines 2008; 7:431-435. (Pubitemid 351656814)
38. Anh DD, Lopez AL, Thiem VD, et al. Use of oral cholera vaccines in an outbreak in Vietnam: a case control study. PLoS Negl Trop Dis 2011; 5:e1006.
39. Noji EK, Lee CY. Natural disaster medicine. In Auerbach P, editor. Wilderness medicine. 5th ed. Philadelphia: Mosby Elsevier; 2007.
40. Reyburn R, Deen JL, Grais RF, et al. The case for reactive mass oral cholera vaccinations. PLoS Negl Trop Dis 2011; 5:e952.
41. Mukandavire Z, Liao S, Wang J, et al. Estimating the reproductive numbers for the 2008-2009 cholera outbreaks in Zimbabwe. Proc Natl Acad Sci U S A 2011; 108:8767-8772.
42. Farmer P, Almazor C, Bahnsen E, et al. Meeting cholera's challenge to Haiti and the world: a joint statement on cholera prevention and care. PLoS Negl Trop Dis 2011; 5:e1145.
43. Chin C-S, Sorenson J, Harris J, et al. The origin of the Haitian cholera outbreak strain. N Engl J Med 2011; 364:33-42.